Skip to content 
FAIRLILY CREAM
COMPOSITION
Hydroquinone 2%w/w+ Mometasone 0.1% & Tretinoin 0.025%
PACK SIZE
20 gm
PACKING
Outer Box
THERAPEUTIC CATEGORY
"Lightening Agent + Anti-inflammatory + Exfoliant"
Verified Exporter
Verified Seller
Trusted Pharma
Uses
This combination cream is commonly used to treat various skin conditions, including:
Melasma: A condition characterized by brown or gray-brown patches on the skin, usually on the face.
Hyperpigmentation: Darkened areas of skin caused by excess melanin production.
Post-inflammatory Hyperpigmentation: Dark spots that appear after an inflammatory skin condition, such as acne or eczema.
Acne: Helps reduce acne lesions and prevent new ones from forming.
Photoaging: Addresses signs of aging caused by sun damage, such as fine lines and wrinkles.
Effect on the Body
Skin Lightening: Hydroquinone reduces dark spots and hyperpigmentation.
Anti-inflammatory Action: Mometasone alleviates inflammation and irritation.
Cell Turnover: Tretinoin promotes cell turnover, improving skin texture and reducing fine lines and acne.
How to Use
Clean and Dry the Affected Area: Wash the area with a gentle cleanser and water, then pat dry.
Apply a Thin Layer: Apply a thin layer of the cream to the affected area, typically at night, as tretinoin can increase sensitivity to sunlight.
Frequency: Usually applied once daily in the evening or as directed by your healthcare provider.
Precautions
Avoid Sensitive Areas: Do not apply to the eyes, mouth, or mucous membranes.
Sun Protection: Use sunscreen during the day and avoid excessive sun exposure, as tretinoin increases photosensitivity.
Allergic Reactions: Discontinue use and consult a healthcare provider if signs of an allergic reaction occur, such as rash, itching, or swelling.
Pregnancy and Breastfeeding: Consult a healthcare provider before use if pregnant or breastfeeding.
Children: Use with caution in children and follow pediatric recommendations.
Related Products
- Featured
- Featured
- Featured
- Featured
Reviews
There are no reviews yet.